The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,516.00
Bid: 12,554.00
Ask: 12,556.00
Change: 112.00 (0.90%)
Spread: 2.00 (0.016%)
Open: 12,500.00
High: 12,586.00
Low: 12,444.00
Prev. Close: 12,404.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Stabilisation Notice

19 Nov 2014 09:41

RNS Number : 4348X
Citigroup Global Markets Limited
19 November 2014
 



19th November 2014

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

 

AstraZeneca PLC

Stabilisation Notice

Citigroup Global Markets Limited. (contact: Syndicate Desk 0207 986 9000) hereby gives notice that the Stabilising Manager(s) named below may stabilise the offer of the following securities in accordance with Commission Regulation (EC) No. 2273/2003 implementing the Market Abuse Directive (2003/6/EC).

 

The securities:

Issuer:

AstraZeneca PLC

Guarantor (if any):

Aggregate nominal amount:

€ TBC

Description:

Senior Unsecured REGS Only

Offer price:

TBC

Other offer terms

Stabilisation:

Stabilising Manager(s):

 Citigroup Global Markets Limited

 

Stabilisation period expected to start on:

19th November 2014

Stabilisation period expected to end no later than:

20th December 2014 (30 days after the proposed issue date of the securities)

Maximum size of over-allotment facility:

5% of the aggregate nominal amount stated above.

 

In connection with the offer of the above securities, the Stabilising Manager(s) may over-allot the securities or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, there is no assurance that the Stabilising Manager(s) will take any stabilisation action and any stabilisation action, if begun, may be ended at any time.

 

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

 

This announcement and the offer of the securities to which it relates are directed only at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom.

 

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive") before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Prospectus Directive (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Directive), this announcement and the offer are only addressed to and directed at persons in that Member State who are qualified investors within the meaning of the Prospectus Directive (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that Member State.

 

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STABLBLTMBIBMMI
Date   Source Headline
1st Aug 201611:00 amRNSDirector/PDMR Shareholding
28th Jul 20167:00 amRNSAZN: H1 2016 Results
27th Jul 20169:00 amRNSNotice of Results
19th Jul 20162:15 pmRNSQTERN (saxa/dapa) EU approved for type-2 diabetes
18th Jul 20167:00 amRNSTAGRISSO MET PRIMARY ENDPOINT IN PHASE III TRIAL
14th Jul 201612:07 pmRNSSecond Price Monitoring Extn
14th Jul 201612:02 pmRNSPrice Monitoring Extension
13th Jul 20167:00 amRNSAZ resolves Faslodex patent litigation in the US
1st Jul 20165:30 pmRNSTotal Voting Rights
28th Jun 20167:00 amRNSZavicefta approved in EU
23rd Jun 20167:00 amRNSAstraZeneca updates on Flumist vaccine in the US
14th Jun 20163:00 pmRNSDirector/PDMR Shareholding
9th Jun 20167:03 amRNSAZ agreement with Aspen for anaesthetics portfolio
3rd Jun 20167:00 amRNSAZ completes US licensing agreement with Ironwood
2nd Jun 20167:00 amRNSAZ LICENSES ZURAMPIC TO GRÜNENTHAL GMBH
1st Jun 201612:00 pmRNSBlock listing Interim Review
1st Jun 201611:30 amRNSTotal Voting Rights
27th May 201612:36 pmRNSPOSITIVE CHMP OPINION IN EU FOR SAXA/DAPA
27th May 20167:03 amRNSPositive results from AstraZeneca Faslodex trial
27th May 20167:00 amRNSAstraZeneca receives CRL from US FDA for ZS-9
23rd May 20164:00 pmRNSDirector/PDMR Shareholding
18th May 20167:00 amRNSTOP-LINE RESULTS FROM LYNPARZA GOLD TRIAL
17th May 20167:00 amRNSPOSITIVE BENRALIZUMAB RESULTS IN SEVERE ASTHMA
12th May 20167:00 amRNSSELUMETINIB GRANTED ORPHAN DRUG DESIGNATION IN US
11th May 20165:30 pmRNSPublication of Final Terms
9th May 20165:35 pmRNSLaunch and pricing of EUR2.2bn bond issues
5th May 20163:00 pmRNSPublication of a Prospectus
3rd May 20161:30 pmRNSTotal Voting Rights
3rd May 20167:01 amRNSAstraZeneca completes divestment of Imdur
3rd May 20167:00 amRNSAZ COMPLETES ACQUISITION OF TAKEDA RESPIRATORY
29th Apr 20165:30 pmRNSResult of AGM
29th Apr 201612:46 pmRNSPOSITIVE CHMP OPINION FOR CAZ AVI
29th Apr 20167:00 amRNSAZN: 1st Quarter Results
28th Apr 20169:00 amRNSNotice of Results
26th Apr 20169:29 amRNSAZ enters US licensing agreement with Ironwood
26th Apr 20167:01 amRNSBEVESPI AEROSPHERE APPROVED BY US FDA FOR COPD
8th Apr 20167:00 amRNSAZ TO CONTINUE PIVOTAL ALZHEIMER'S CLINICAL TRIAL
1st Apr 201611:30 amRNSTotal Voting Rights
29th Mar 20167:00 amRNSTAGRISSO APPROVED IN JAPAN FOR CANCER PATIENTS
24th Mar 20163:00 pmRNSDirector/PDMR Shareholding
23rd Mar 20167:00 amRNSAZ reports results from Brilinta stroke trial
18th Mar 201610:30 amRNSNotice of AGM
8th Mar 20166:29 pmRNSFiling of Form 20-F with SEC
8th Mar 201612:00 pmRNSAnnual Financial Report
1st Mar 20162:30 pmRNSTotal Voting Rights
29th Feb 20161:45 pmRNSAZ REPORTS TOP-LINE RESULT OF TREMELIMUMAB TRIAL
29th Feb 20167:59 amRNSAZ enters licensing agreement with CMS for Plendil
26th Feb 201612:00 pmRNSDirector/PDMR Shareholding
25th Feb 20168:57 amRNSACALABRUTINIB ORPHAN DRUG DESIGNATION RECOMMENDED
19th Feb 20167:05 amRNSBRILIQUE APPROVED IN EU FOR HEART ATTACK PATIENTS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.